242 related articles for article (PubMed ID: 27194387)
41.
Kowal K; Bielecki P; DuBuske IV; DuBuske LM
Allergy Asthma Proc; 2017 May; 38(3):204-215. PubMed ID: 28441991
[TBL] [Abstract][Full Text] [Related]
42. Role of the IgE variable heavy chain in FcεRIα and superantigen binding in allergy and immunotherapy.
Lua WH; Su CT; Yeo JY; Poh JJ; Ling WL; Phua SX; Gan SK
J Allergy Clin Immunol; 2019 Aug; 144(2):514-523.e5. PubMed ID: 30995457
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms of action of anti-immunoglobulin E therapy.
Soresi S; Togias A
Allergy Asthma Proc; 2006; 27(2 Suppl 1):S15-23. PubMed ID: 16722327
[TBL] [Abstract][Full Text] [Related]
44. Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature.
Li JX; Fan LC; Li MH; Cao WJ; Xu JF
Respir Med; 2017 Jan; 122():33-42. PubMed ID: 27993289
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of IgE-dependent histamine release from human peripheral blood basophils by humanized Fab fragments that recognize the membrane proximal domain of the human Fc epsilon RI alpha-chain.
Takai T; Yuuki T; Ra C
Int Arch Allergy Immunol; 2000 Dec; 123(4):308-18. PubMed ID: 11146388
[TBL] [Abstract][Full Text] [Related]
46. Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab.
Zaidi AK; Saini SS; Macglashan DW
J Allergy Clin Immunol; 2010 Apr; 125(4):902-908.e7. PubMed ID: 20236696
[TBL] [Abstract][Full Text] [Related]
47. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3
Benito-Villalvilla C; de la Rocha-Muñoz A; López-Abente J; Eggel A; Bottoli I; Severin T; Woisetschläger M; Palomares O
Allergy; 2023 Apr; 78(4):1060-1072. PubMed ID: 36315052
[TBL] [Abstract][Full Text] [Related]
48. [The high-affinity IgE receptor: lessons from structural analysis].
Blank U; Jouvin MH; Guérin-Marchand C; Kinet JP
Med Sci (Paris); 2003 Jan; 19(1):63-9. PubMed ID: 12836193
[TBL] [Abstract][Full Text] [Related]
49. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.
Messingham KN; Pietras TA; Fairley JA
G Ital Dermatol Venereol; 2012 Jun; 147(3):251-7. PubMed ID: 22648326
[TBL] [Abstract][Full Text] [Related]
50. Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies.
Vigl B; Salhat N; Parth M; Pankevych H; Mairhofer A; Bartl S; Smrzka OW
J Immunol Methods; 2017 Oct; 449():28-36. PubMed ID: 28647457
[TBL] [Abstract][Full Text] [Related]
51. The crystal structure of IgE Fc reveals an asymmetrically bent conformation.
Wan T; Beavil RL; Fabiane SM; Beavil AJ; Sohi MK; Keown M; Young RJ; Henry AJ; Owens RJ; Gould HJ; Sutton BJ
Nat Immunol; 2002 Jul; 3(7):681-6. PubMed ID: 12068291
[TBL] [Abstract][Full Text] [Related]
52. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
D'Amato G
Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
[TBL] [Abstract][Full Text] [Related]
53. Omalizumab for treatment of allergic rhinitis.
Vashisht P; Casale T
Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
[TBL] [Abstract][Full Text] [Related]
54. Possible therapeutic role of IgE blockade in irritable bowel syndrome.
Magen E; Chikovani T
World J Gastroenterol; 2016 Nov; 22(43):9451-9456. PubMed ID: 27920467
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of omalizumab in paediatric age: an update of literature data.
Matin N; Tabatabaie O; Falsaperla R; Pavone P; Serra A; Cocuzza S; Di Mauro P; Licciardello L; Lubrano R; Vitaliti G
J Biol Regul Homeost Agents; 2016; 30(2):579-84. PubMed ID: 27358151
[TBL] [Abstract][Full Text] [Related]
56. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation.
Zhu D; Kepley CL; Zhang M; Zhang K; Saxon A
Nat Med; 2002 May; 8(5):518-21. PubMed ID: 11984598
[TBL] [Abstract][Full Text] [Related]
57. [Progress in the study of allergic disease drugs targeting on IgE/FcepsilonRI signaling pathway].
Liu ZC; Shi HL; Zhang YF; Zhao LJ
Yao Xue Xue Bao; 2011 Oct; 46(10):1161-6. PubMed ID: 22242444
[TBL] [Abstract][Full Text] [Related]
58. Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor.
McDonnell JM; Beavil AJ; Mackay GA; Jameson BA; Korngold R; Gould HJ; Sutton BJ
Nat Struct Biol; 1996 May; 3(5):419-26. PubMed ID: 8612071
[TBL] [Abstract][Full Text] [Related]
59. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis.
Baker DL; Nakamura GR; Lowman HB; Fischer SK
AAPS J; 2016 Jan; 18(1):115-23. PubMed ID: 26340860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
